Use of serotonin selective reuptake inhibitors in geriatric depression

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 5, 1996, Pages 12-22

  Newhouse, Paul A ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGED; DEPRESSION; DIARRHEA; DRUG INDUCED DISEASE; GERIATRIC PATIENT; GERONTOPSYCHIATRY; HUMAN; INSOMNIA; MENTAL PATIENT; NAUSEA; PRIORITY JOURNAL; REVIEW;

1-NAPHTHYLAMINE; AGE FACTORS; AGED; CONTROLLED CLINICAL TRIALS; DEPRESSIVE DISORDER; FLUOXETINE; FLUVOXAMINE; HUMANS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 0030008558     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Blazer D, Williams CD. Epidemiology of dysphoria and depression in an elderly population. Am J Psychiatry 1980;137:439-444
2. Okimoto JT, Barnes RF, Veith RC. Screening for depression in geriatric medical patients. Am J Psychiatry 1982;139:799-802
3. Kitchell MA, Barnes RF, Veith RC. Screening for depression in hospitalized geriatric medical patients. J Am Geriatr Soc 1982;30:174-177
4. Rapp SR, Parisi SA, Walsh DA. Psychological dysfunction and physical health among elderly medical inpatients. J Consult Clin Psychol 1988;56: 851-855
5. Blazer D. Depression in the elderly. N Engl J Med 1989;320:164-166
6. Allen A, Blazer DG. Mood disorders. In: Sadavoy J, Lazarus LW, Jarvik LF, eds. Comprehensive Review of Geriatric Psychiatry. Washington, DC: American Psychiatric Press; 1991:337-352
7. Katz IR, Curlik S, Nemetz P. Functional psychiatric disorders in the elderly. In: Jarvik LF, Foster JR, Lieff JD, et al. Essentials of Geriatric Psychiatry. New York, NY: Springer; 1988:113-137
8. Borson S, Barnes RA, Kukull WA. Symptomatic depression in elderly medical outpatients, I: prevalence, demography, and health service utilization. J Am Geriatr Soc 1986:34:341-347
9. Berkman LF, Berkman CS, Kasl S. Depressive symptoms in relation to physical health and functioning in the elderly. Am J Epidemiol 1986; 124:372-388
10. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 1989; 262:914-919
11. Brodaty H, Harris L, Peters K, et al. Prognosis of depression in the elderly: a comparison with younger patients. Br J Psychiatry 1993;163:589-596
12. Dunner DL. An overview of paroxetine in die elderly. Gerontology 1994; 40:21-27
13. Cavanaugh S, Clark DC, Gibbons RD. Diagnosing depression in the hospitalized medically ill. Psychosomatics 1983;24:809-815
14. Dietch JT, Fine M. The effect of nortriptyline in elderly patients with cardiac conduction disease. J Clin Psychiatry 1990;51:65-67
15. Abrams R. Anxiety and personality disorders. In: Sadavoy J, Lazarus LW, Jarvik JF, eds. Comprehensive Review of Geriatric Psychiatry. Washington, DC: American Psychiatric Press; 1991:369-386
16. Koenig HG, Meador KG, Cohen HG, et al. Detection and treatment of major depression in older medically ill hospitalized patients. Int J Psychiatry Med 1988;18:17-31
17. Glassman AH, Roose SP. Risks of antidepressants in the elderly: tricyclic antidepressants and arrhythmia - revising risks. Gerontology 1994;40 (suppl): 15-20
18. Marcopulos BA, Graves RE. Antidepressant effect on memory in depressed older patients. J Clin Exp Neuropsychol 1990;12:655-663
19. Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:513-526
20. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967; 113:1237-1247
21. Lapin IP, Oxenkrug GF. Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. Lancet 1969; 1:132-136
22. Murphy DL, Campbell I, Costa JL. Current status of the indolamine hypothesis of the affective disorders. In: DiMascio A, Killam KF, eds. Psychopharmacology: A Generation of Progress. New York, NY: Raven Press; 1978:1235-1247
23. Delgado PL, Price LH, Miller HL, et al. Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994;51:865-874
24. Benkelfat D, Ellenbogen MA, Dean P, et al. Mood-lowering effect of tryptophan depletion: enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 1994;51:687-697
25. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new serotonin selective reuptake inhibitors. Clin Pharm 1992;11:930-957
26. Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992;43:3-10
27. Finkel SI. Efficacy and tolerability of antidepressant therapy in the old-old. J Clin Psychiatry 1996;57(suppl 5):23-28
28. Seth R, Jennings AL, Bindman J, et al, Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565
29. Tollefson GD, Holman SL. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol 1993;8:253-259
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987:228-230
31. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985;46(3, sec 2):20-25
32. Altamura AC, Percudani M, Guercetti G, et al. Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitriptyline. J Clin Psychopharmacol 1989;4(suppl 1):103-106
33. Falk WE, Rosenbaum JF, Otto MW. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol 1989;2:208-214
34. Brymer C, Winograd CH. Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 1992;40:902-905
35. Spier SA, Frontera MA. Unexpected deaths in depressed medical inpatients treated with fluoxetine. J Clin Psychiatry 1991;52:377-382
36. Leinonen E, Koponen H, Lepola U. Delirium during fluoxetine treatment: a case report. Ann Clin Psychiatry 1993;5:255-257
37. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990;51(12, suppl B):28-33
38. Newhouse PA, Richter E. A double-blind comparison of sertraline and fluoxetine in elderly depressed outpatients. Presented at the 33rd annual meeting of the American College of Neuropsychopharmacology; 1994; San Juan, Puerto Rico
39. McEntee WJ, Coffey DJ, Bondareff W, et al. A double-blind comparison of sertraline and nortriptyline in the treatment of depressed geriatric outpatients. Presented at the 148th annual meeting of the American Psychiatric Association; May 20-25, 1995; Miami, Fla
40. Jenkyn LR, Coffey DJ, Coffey AK, et al. Effects of antidepressants on cognitive and motor functions in the elderly. Presented at the 49th annual meeting of the American Geriatric Society; November 14-18, 1992; Washington, DC
41. Dunner DL, Cohn JB, Walshe T III, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992;53(2, suppl):57-60
42. Hutchinson DR, Jong S, Moon CAL, et al. A double-blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients. Br J Clin Res 1991;2:43-57
43. Guillibert E, Pelicier Y, Archambault JC, et al. A double-blind, multicenter study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989;80:132-134
44. Samuelian JC. Comparison of efficacy and safety of increasing doses of paroxetine and clomipramine in elderly patients [abstract]. Biol Psychiatry 1991;29(suppl):635S
45. Rahman MK, Akhtar MJ, Salva NC, et al. A double-blind, randomized comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. Br J Clin Pract 1991;45:255-258
46. Bocksberger JP, Gachoud JP, Richard J, et al. Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. Eur Psychiatry 1993:8:319-324
47. Moon CAL, Jesinger DK. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. Br J Clin Pract 1991;45:259-262
48. Laird LK, Lydiard RB, Morton WA, et al. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry 1993;54:224-228
49. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993;94(suppl 5A):2S-12S
50. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52:1023-1029
51. Sprouse J, Clarke T, Reynolds L, et al. Comparison of the effects of sertraline and its metabolite methylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 1996;14:225-231
52. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991;6(suppl 2):11-21
53. Preskorn SH, Magnus RD. Inhibition of hepatic P450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1994;30:251-259
54. Preskorn SH, Alderman J, Harris S, et al. Desipramine levels after sertraline or fluoxetine. Presented at the annual meeting of the American Psychiatric Association; May 2-7, 1992; Washington, DC
55. Zussman BD, Davie CC, Fowles SE, et al. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Presented at the 33rd annual meeting of the American College of Neuropsychopharmacology; December 12-16,1994; San Juan, Puerto Rico
56. Kurtz DJ, Bergstrom RF, Goldberg MJ, et al, Drug interaction between sertraline and desipramine or imiprarnine. J Clin Pharmacol 1994;34:1009-1033
57. Lawlor BA, Newhouse PA, Balkin T, et al. A preliminary study of the effects of the serotonin agonist m-CPP on sleep architecture and behavior in healthy volunteers. Biol Psychiatry 1991;29:281-286
58. Preskorn SH. Clinical Pharmacology of SSRIs: The Basis for Their Optimal Clinical Use. Caddo, Okla: Professional Communications Inc; 1995
59. Blacksten JV, Birt JA, Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine. Ann Pharmacother 1993;27:723-724
60. Llorente MD, Gorelick M, Silverman MA. Sertraline as the cause of inappropriate antidiuretic hormone secretion [letter]. J Clin Psychiatry 1994; 55:543-544
61. Schou M. Lithium and treatment resistant depressions: a review. Lithium 1990;1:3-8
62. Kushnir SL. Litnium-antidepressant combinations in the treatment of depressed, physically ill geriatric patients. Am J Psychiatry 1986;143:378-379
63. Weilburg JB, Rosenbaum JF, Biederman J, et al, Fluoxetine added to nonMAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-449
64. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54:269-271
65. Reynolds CF, Perel JM, Frank E, et al. Open-trial maintenance pharmacotherapy in late-life depression: survival analysis. Psychiatry Res 1989;27:225-231
66. Georgatas A, McCue RE, Cooper TB, et al. How effective and safe is continuation therapy in elderly depressed patients? factors affecting relapse rate. Arch Gen Psychiatry 1988;45:929-932
67. Reynolds CF, Frank E, Kupfer DJ, et al. Acute and continuation treatment outcome in recurrent major depression: comparison of elderly and midlife patients. Presented at the 34th annual meeting, American College of Neuropsychopharmacology, December 11-15,1995; San Juan, Puerto Rico
68. Reynolds CF III. Treatment of depression in special populations. J Clin Psychiatry 1992;53:45-53
69. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990;51(6, suppl):60-69
70. Robinson RG, Starr LB, Price TR. A two-year longitudinal study of poststroke mood disorders: prevalence and duration at six month follow-up. Br J Psychiatry 1984;144:256-262
71. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the serotonin selective reuptake inhibitor citalopram. Stroke 1994;25:1099-1104
72. Panzer MJ, Mellow AM. Antidepressant treatment of pathologic laughing or crying in elderly stroke patients. J Geriatr Psychiatry Neurol 1992;5:195-199
73. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-454
74. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992;53:278-282
75. Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly pa-tients with and without dementia disorders. Int J Clin Psychopharmacol 1992;6(suppl 5):55-64
76. Burke WJ, Folks DG, Roccaforte WH, et al. Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dementia of the Alzheimer type. Am J Geriatr Psychiatry 1994;2:352-354
77. Gottfries CG, Nyth AL. Effect of citalopram, a selective 5-HT reuptake blocker in emotionally disturbed patients with dementia. Ann N Y Acad Sci 1991;640:276-279
78. Jonsson B, Bebbington PE. What price depression? the cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-673
79. Brosen K. Isoenzyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nordic Journal of Psychiatry 1993;47(suppl 30): 21-26